OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical firm devoted to the invention and improvement of novel immunotherapies, immediately introduced that the US Patent and Trademark Workplace (USPTO) has issued U.S. Patent No. 12,059,459, entitled, Therapeutic Anticancer Neoepitope Vaccine.
The newly issued patent describes Nykode’s totally individualized neoantigen primarily based vaccine, VB10.NEO, which is in improvement for the remedy of regionally superior or metastatic stable tumours. The 20 12 months expiration date of this patent is January 5, 2037. Associated patents had been beforehand granted to the corporate in Russia, India, and Australia.
Michael Engsig, CEO of Nykode, mentioned, We’re more than happy with the granting of this necessary patent within the U.S., a key marketplace for Nykode. Repeatedly increasing our patent safety is a core technique for us. The granting of this patent is a testomony to the world-class innovation happening in Nykode’s labs. We stay devoted to pushing the boundaries of what is attainable in medication, bringing hope to sufferers and their households across the globe.
About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen vaccine in improvement for the remedy of regionally superior or metastatic stable tumors beneath an unique, worldwide medical collaboration with Genentech, a member of the Roche Group. The vaccine is designed to be produced on-demand in accordance with the neoantigen profile of a person affected person. Neoantigens are proteins generated by tumor-specific mutations not current in regular tissues and are thus a sexy goal for most cancers immunotherapy as they could be acknowledged as overseas by the immune system.
Nykode is at the moment conducting a medical examine evaluating VB10.NEO: VB N-02, an open-label Part 1b, dose-escalation examine of the protection and antigen-specific immune responses elicited by VB10.NEO together with Roche’s checkpoint inhibitor atezolizumab in sufferers with regionally superior and metastatic tumors (NCT05018273).
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical firm devoted to the invention and improvement of novel immunotherapies with a give attention to the remedy of most cancers and autoimmune ailments. Nykode’s modular vaccine expertise particularly targets antigens to antigen presenting cells (APC), which have been proven to induce a broad, robust and long-lasting antigen particular immune response in most cancers, which correlates with medical responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the remedy of HPV16 induced malignancies which demonstrated favorable security and efficacy outcomes from its Part 2 trial for the remedy of cervical most cancers. VB10.16 is being expanded into a number of trials for remedy of head and neck most cancers and cervical most cancers. VB10.NEO, an individualized most cancers neoantigen vaccine, is solely out-licensed to Genentech, a member of the Roche Group.
The Firm’s partnerships embrace Genentech inside oncology and a multi-target collaboration with Regeneron (NASDAQ:) in oncology and infectious ailments.
Nykode can also be using its APC-targeted expertise to create an inverse vaccine platform for the potential use in autoimmune problems, organ transplant rejections, anti-drug antibody reactions and allergy.
Nykode Therapeutics’ shares are traded on the Oslo Inventory Change (OSE: NYKD). Additional details about Nykode Therapeutics may be discovered at http://www.nykode.com.
Ahead-looking statements for Nykode Therapeutics
This announcement and any supplies distributed in reference to this announcement could comprise sure forward-looking statements. By their nature, forward-looking statements contain threat and uncertainty as a result of they mirror the corporate’s present expectations and assumptions as to future occasions and circumstances that won’t show correct. Quite a lot of materials components may trigger precise outcomes and developments to vary materially from these expressed or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Supply: Nykode Therapeutics ASA
